Going to extremes: determinants of extraordinary response and survival in patients with cancer
Flurina A.M. Saner(University of Bern), David D.L. Bowtell(The University of Melbourne), Ellen L. Goode(Mayo Clinic in Arizona), Anna DeFazio(The University of Sydney), Andrew Berchuck(General Marble (Greece)), Susan J. Ramus(Cancer Institute of New South Wales), Sián Fereday(Peter MacCallum Cancer Centre), Brad H. Nelson(University of British Columbia), Jessica A. Beach(Samueli Institute), Malcolm C. Pike(Kettering University), Ahwan Pandey(Howard Hughes Medical Institute), Dale W. Garsed(Peter MacCallum Cancer Centre), Paul D.P. Pharoah(Cedars-Sinai Medical Center), Celeste Leigh Pearce(University of Southern California), Stéphanie Lheureux(Princess Margaret Cancer Centre), Alan Herschtal(Peter MacCallum Cancer Centre)
Cited by 51
Related Papers
Integrated genomic analyses of ovarian carcinoma
|Nature|2011|8.2k
Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies
|The American Journal of Human Genetics|2003|3.7k
The clonal and mutational evolution spectrum of primary triple-negative breast cancers
|Nature|2012|2k
The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes
|Nature Communications|2016|1.8k